Home Cart Sign in  
Chemical Structure| 73285-50-4 Chemical Structure| 73285-50-4

Structure of 1-Deoxynojirimycin HCl
CAS No.: 73285-50-4

Chemical Structure| 73285-50-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Deoxynojirimycin HCl, a natural product isolated and purified from the root barks of Morus alba L., shows inhibitory activity against α-glucosidases, inhibitors of α-glucosidase are promising candidates for the development of antitype II diabetics and anti-AIDS drugs.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 1-Deoxynojirimycin HCl

CAS No. :73285-50-4
Formula : C6H14ClNO4
M.W : 199.63
SMILES Code : O[C@@H]1[C@@H](CO)NC[C@H](O)[C@H]1O.[H]Cl
MDL No. :MFCD00133247
InChI Key :ZJIHMALTJRDNQI-VFQQELCFSA-N
Pubchem ID :13018787

Safety of 1-Deoxynojirimycin HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H332
Precautionary Statements:P261-P264-P280-P301+P312-P302+P352+P312-P304+P340+P312

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01380743 Pompe Disease Phase 2 Completed - United States, Arizona ... More >> Phoenix, Arizona, United States, 85018 Scottsdale, Arizona, United States, 85258 United States, California Orange, California, United States, 92868 United States, Florida Gainesville, Florida, United States, 32610 United States, Georgia Decatur, Georgia, United States, 30033 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Montana Great Falls, Montana, United States, 59405 United States, North Carolina Durham, North Carolina, United States, 27710 United States, Ohio Cincinnati, Ohio, United States, 45299 United States, Oregon Portland, Oregon, United States, 97239 United States, Virginia Springfield, Virginia, United States, 22152 Canada, Ontario Hamilton, Ontario, Canada, L8N 3Z5 France Paris, France, 75013 United Kingdom London, Queen Square, United Kingdom, WC1N 3BG Salford, United Kingdom, M68 HD Less <<
NCT01853852 Fabry Disease Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Less <<
NCT02194985 Fabry Disease Phase 3 Active, not recruiting October 2019 -
NCT01489995 Fabry Disease Phase 1 Completed - United States, Texas ... More >> GSK Investigational Site Austin, Texas, United States, 78744 Less <<
NCT01380743 - Completed - -
NCT00304512 Fabry Disease Phase 2 Completed - United States, Georgia ... More >> Decatur, Georgia, United States, 30033 Australia, Victoria Parkville, Victoria, Australia, 3050 Brazil Porto Alegre, Brazil, RS, 90035-903 Canada Montréal, Canada, H4J 1C5 France Paris, France, 75015 United Kingdom Salford, United Kingdom, M6 8HD Less <<
NCT00925301 Fabry Disease Phase 3 Completed - -
NCT00304512 - Completed - -
NCT01458119 - Terminated(Amicus Therapeutics... More >> discontinued Study AT1001-041 for logistical reasons.) Less << - -
NCT00925301 - Completed - -
NCT02082327 Fabry Disease Phase 1 Completed - Netherlands ... More >> PRA International Groningen, Netherlands, 9713 GZ Less <<
NCT01458119 Fabry Disease Phase 3 Terminated(Amicus Therapeutics... More >> discontinued Study AT1001-041 for logistical reasons.) Less << - -
NCT00688597 Pompe Disease Phase 2 Terminated(Per protocol, 3 seq... More >>uential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.) Less << - United States, Georgia ... More >> Decatur, Georgia, United States, 30033 Less <<
NCT00688597 - Terminated(Per protocol, 3 seq... More >>uential dose cohorts were planned. Study discontinued by Sponsor based upon serious adverse events in first 2 of 3 participants in Cohort 1.) Less << - -
NCT01730482 Fabry Disease Phase 1 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.01mL

1.00mL

0.50mL

25.05mL

5.01mL

2.50mL

50.09mL

10.02mL

5.01mL

References

 

Historical Records

Categories